Shenjun Li

Title: Shenjun Li: Innovator in Cancer Treatment

Introduction

Shenjun Li is a prominent inventor based in Shandong, China. He has made significant contributions to the field of immunotherapy, particularly in the development of treatments for cancer. His innovative work has led to the creation of a valuable patent that addresses critical medical needs.

Latest Patents

Shenjun Li holds a patent for an "Anti PD-L1 antibody and use thereof." This invention provides a PD-L1 immunosuppressant, specifically a monoclonal antibody capable of targeting PD-L1. The patent also includes nucleotides, combinations of polynucleotides, expression vectors, and combinations of expression vectors encoding the antibody. Furthermore, it describes a conjugate or pharmaceutical composition containing the anti PD-L1 antibody. The invention is aimed at the preparation of a medicament for treating or preventing cancers.

Career Highlights

Shenjun Li is associated with Remegen Co., Ltd., a company known for its focus on innovative biopharmaceuticals. His work at Remegen has positioned him as a key player in the development of new cancer therapies. With a patent portfolio that includes 1 patent, he continues to push the boundaries of medical science.

Collaborations

Shenjun Li has collaborated with notable colleagues, including Jing Jiang and Jianmin Fang. These partnerships have enhanced the research and development efforts within his field, contributing to advancements in cancer treatment.

Conclusion

Shenjun Li's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work at Remegen Co., Ltd. and collaborations with esteemed colleagues further highlight his impact in the field of immunotherapy.